US2016251448A1PendingUtilityA1

Method of increasing the effect of an activated-potentiated form of an antibody

50
Assignee: EPSHTEIN OLEG ILIICHPriority: Jul 15, 2010Filed: Mar 3, 2016Published: Sep 1, 2016
Est. expiryJul 15, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:Oleg Iliich Epshtein
A61P 3/10A61P 9/00A61P 7/10A61P 43/00A61P 9/10A61P 9/12A61P 25/18A61P 25/22A61P 25/28A61P 25/24A61P 1/08A61P 13/08A61P 25/00A61P 15/10A61P 1/00A61K 39/395A61K 41/0004A61K 39/3955C07K 16/2869C07K 16/40C07K 16/18A61K 2039/507A61K 9/20C07K 16/28
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The preset invention provides a method of increasing the effect of an activated-potentiated form of an antibody to an endogenous biological molecule by combining said endogenous biological molecule with an activated-potentiated form of an antibody to endothelial NO-synthase. The present invention also provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to an endogenous biological molecule, and b) an activated-potentiated form of an antibody to NO synthase.

Claims

exact text as granted — not AI-modified
1 .- 6 . (canceled) 
     
     
         7 . A pharmaceutical composition comprising a) an activated-potentiated form of an antibody to an endogenous biological molecule, and b) an activated-potentiated form of an antibody to NO synthase. 
     
     
         8 . The pharmaceutical composition of  claim 7 , further comprising pharmaceutically acceptable solid carrier. 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein said activated-potentiated form of an antibody to endothelial NO-synthase is in the form of a mixture of C12, C30, and C200 homeopathic dilutions impregnated onto said solid carrier. 
     
     
         10 . The pharmaceutical composition of  claim 7 , wherein said activated-potentiated form of an antibody to an endogenous biological molecule is a monoclonal, monoclonal, or natural antibody. 
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein said antibody to an endogenous biological molecule is a polyclonal antibody. 
     
     
         12 . The pharmaceutical composition of  claim 7 , wherein said activated-potentiated form of an antibody to an endogenous biological molecule is prepared by successive centesimal dilutions coupled with shaking of every dilution. 
     
     
         13 . The pharmaceutical composition of  claim 7 , wherein said antibody to endothelial NO-synthase is monoclonal, polyclonal or natural antibody. 
     
     
         14 . The pharmaceutical composition of  claim 8 , wherein said antibody to endothelial NO-synthase is a polyclonal antibody. 
     
     
         15 . The pharmaceutical composition of  claim 9 , the activated-potentiated form of an antibody to endothelial NO-synthase is prepared by successive centesimal dilutions coupled with shaking of every dilution.

Join the waitlist — get patent alerts

Track US2016251448A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.